COVID-19, caused by SARS-CoV-2, is a highly contagious disease with variable clinical presentation. Severe forms are more common in patients with pre-existing chronic conditions. The objective of this study is to evaluate the prognostic value of the Charlson Comorbidity Index (CCI) in relation to disease severity and outcome in hospitalized COVID-19 patients with comorbidities. A retrospective analysis was conducted on 558 patients, hospitalized at the Infectious Diseases Clinic of “St. Marina” University Hospital, Varna, Bulgaria, between March 2020 and March 2021. CCI score was calculated to estimate 10-year survival probabilities. Prevalent comorbidities were arterial hypertension (78.55%), type 2 diabetes (16.09%), and ischemic heart disease (5.82%). A higher number of comorbidities was associated with increased rates of bilateral pulmonary consolidation (χ2 = 6.63, p = 0.010), oxygen therapy needs (χ2 = 5.41, p = 0.020), and mortality (χ2 = 7.88, p = 0.005). Patients with higher CCI scores had worse outcomes. A CCI score above 5 was common among non-survivors and those with pulmonary consolidation and respiratory failure. The findings confirm that advanced age and multiple comorbidities are strong predictors of poor COVID-19 prognosis. Early CCI calculation at hospital admission would help identify high-risk patients and support timely, targeted medical interventions.
Background: Typhoid fever (TF) is a systemic infection caused by Salmonella enterica serovar Typhi, typically associated with regions where sanitation and access to clean water are inadequate. Although rare in non-endemic countries, TF remains a diagnostic consideration in travelers returning from endemic areas with febrile illness. Case report: We present the case of an 18-year-old female who developed TF following recent travel to Nigeria. The initial clinical presentation, including fever, dysuria, and abdominal pain, led to a misdiagnosis of acute pyelonephritis. Malaria, arboviral infections, acute viral hepatitis, and parasitic diseases were systematically ruled out through clinical evaluation, serological testing, and parasitological analysis. The clinical course was marked by fever, abdominal pain, somnolence, and hematological and hepatic abnormalities. Blood cultures confirmed the diagnosis, with the isolate verified and serotyped by the National Center of Infectious and Parasitic Diseases. Targeted antimicrobial treatment with ceftriaxone and levofloxacin resulted in full recovery, with no evidence of relapse or chronic carriage over a three-month follow-up period. Conclusions: This case highlights the critical importance of a structured differential diagnostic approach and microbiological confirmation in febrile patients with relevant travel history. In non-endemic settings, where TF may be underrecognized, early recognition, pathogen identification, and appropriate antimicrobial therapy remain essential to favorable outcomes and public health safety.
Introduction: COVID-19 is caused by SARS-CoV-2. Individuals with type 2 diabetes mellitus are a main risk group for its severe and often fatal course. Aim: In this review we examine the pathogenetic relationship, clinical outcome, and current therapeutic strategies in patients with type 2 diabetes mellitus, suffering from COVID-19. Material and Methods: Data from international studies were integrated, with particular focus on hospitalized patients from the targeted group. Pathophysiological mechanisms, risk factors, and outcomes were systematically analyzed. Results and Discussion: Diabetes mellitus is associated with impaired innate and adaptive immunity, chronic systemic inflammation, endothelial dysfunction, and a prothrombotic state. Hyperglycemia and insulin resistance increase ACE2 and furin expression, facilitating viral entry and its replication. In diabetic patients with COVID-19, higher rates of hospitalization, intensive care admission, and the need for mechanical ventilation are frequently reported. Optimal glycemic control is crucial, as both hyper- and hypoglycemia worsen the outcomes. Insulin remains the preferred therapeutic agent in hospitalized patients, with emerging evidence supporting the use of SGLT-2 and DPP-4 inhibitors. Conclusion: Type 2 diabetes mellitus is a significant risk factor for severe COVID-19. The underlying pathogenesis involves a complex interplay of immune dysfunction, chronic inflammation, endothelial damage, and metabolic regulation, indicating bidirectional relationship. Achieving optimal glycemic control, managing comorbidities, and ensuring early medical intervention are essential strategies for improving prognosis in this high-risk population.
Introduction: Coronaviruses were traditionally associated with mild respiratory illness until the emergence of SARS-CoV, MERS-CoV, and more recently SARS-CoV-2, the causative agent of COVID-19. HIV infection, characterized by progressive immunosuppression, raises important considerations in the context of SARS-CoV-2 co-infection. Aim: The aim of this article is to evaluate the clinical, immunological, and therapeutic intersections between HIV and COVID-19. Materials and Methods: A targeted review of peer-reviewed literature and relevant clinical data was conducted to explore the interaction between SARS-CoV-2 and HIV, focusing on clinical course, outcomes, and prognosis in co-infected patients. Results and Discussion: Current evidence indicates that HIV-positive individuals, particularly those receiving antiretroviral therapy (ART), are not at significantly increased risk of severe COVID-19 compared to the general population. In certain cases, lower CD4+ T-cell counts may attenuate hyper-inflammatory responses such as cytokine storm. However, co-infection may elevate thrombotic risk and complicate clinical management. The COVID-19 pandemic also disrupted HIV care and treatment continuity, potentially affecting long-term outcomes. Conclusion: While current data are reassuring regarding COVID-19 severity in HIV-positive patients on ART, the evolving nature of SARS-CoV-2 and the persistent global burden of HIV underscore the need for continued research and preparedness in managing of this co-infection.
Background: Typhoid fever (TF) is a systemic infection caused by Salmonella enterica serovar Typhi, typically associated with regions where sanitation and access to clean water are inadequate. Although rare in non-endemic countries, TF remains a diagnostic consideration in travelers returning from endemic areas with febrile illness. Case report: We present the case of an 18-year-old female who developed TF following recent travel to Nigeria. The initial clinical presentation, including fever, dysuria, and abdominal pain, led to a misdiagnosis of acute pyelonephritis. Malaria, arboviral infections, acute viral hepatitis, and parasitic diseases were systematically ruled out through clinical evaluation, serological testing, and parasitological analysis. The clinical course was marked by fever, abdominal pain, somnolence, and hematological and hepatic abnormalities. Blood cultures confirmed the diagnosis, with the isolate verified and serotyped by the National Center of Infectious and Parasitic Diseases. Targeted antimicrobial treatment with ceftriaxone and levofloxacin resulted in full recovery, with no evidence of relapse or chronic carriage over a three-month follow-up period. Conclusions: This case highlights the critical importance of a structured differential diagnostic approach and microbiological confirmation in febrile patients with relevant travel history. In non-endemic settings, where TF may be underrecognized, early recognition, pathogen identification, and appropriate antimicrobial therapy remain essential to favorable outcomes and public health safety.